{
    "clinical_study": {
        "@rank": "35060", 
        "arm_group": [
            {
                "arm_group_label": "Botulinum toxin type A(Botox\u00ae)", 
                "arm_group_type": "Active Comparator", 
                "description": "Botulinum toxin type A"
            }, 
            {
                "arm_group_label": "Botulinum toxin type A (Botulax\u00ae)", 
                "arm_group_type": "Experimental", 
                "description": "Botulinum toxin type A"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the safety and efficacy of Botulax\u00ae with Botox\u00ae in the improvement of moderate to\n      severe glabellar lines."
        }, 
        "brief_title": "To Evaluate the Safety and Efficacy of Botulax\u00ae Are Not Inferior to Those of Botox\u00ae in the Treatment of Glabellar Lines", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": "Skin Aging", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women aged between 18 and 65\n\n          -  Patients attaining grade 2 or 3 in the investigator's rating of glabellar lines\n             severity at maximum frown\n\n          -  Patients who voluntarily sign the informed consent\n\n          -  Patients who can comply with the study procedures and visit schedule\n\n        Exclusion Criteria:\n\n          -  Subjects who had facial plastic surgery (tissue augmentation, brow lift, and dermal\n             resurfacing)treatment within 6 months. Those who had peeling or laser therapy\n\n          -  Subjects with skin disorders, scar or infection around glabellar region\n\n          -  Subjects who are taking Aspirin, NSAIDS or anti-coagulant\n\n          -  Subjects with facial palsy or eyelid ptosis\n\n          -  Subjects who diagnosed as neuromuscular junction disorder (e.g., myasthenia gravis,\n             Lambert-Eaton Syndrome)\n\n          -  Subjects with history of drug intoxication, alcohol abuse and/or depressive disorder\n\n          -  Subjects with severe internal diseases (cardiovascular, respiratory, renal disease,\n             liver disorder)\n\n          -  Subjects who have previously been treated with botulinum toxin within 3 months\n             (Botulinum toxin type A: 3months, type B: 4 months)\n\n          -  Subject who have administered following drugs within the previous 4 months:\n             Spectinomycin Hydrochloride, Aminoglycoside antibiotics, polypeptide antibiotics,\n             tetracycline antibiotics, lincomycin antibiotics, muscle relaxants, anti-cholinergic\n             agents, benzodiazepine and similar drugs, benzamide drugs, Tubocurarine-type muscle\n             relaxants\n\n          -  Subjects who have possibility to take the drugs listed above\n\n          -  Subjects who have a plan to receive facial cosmetic procedures including dermal\n             filler, chemical peeling and dermabrasion during study period\n\n          -  Subjects who have glabellar lines that are unable to be improved with any physical\n             method\n\n          -  Subjects who have history of hypersensitivity to Botulinum toxin and other agents\n\n          -  Subjects who are pregnant or breast-feeding\n\n          -  Subjects who have a plan to be pregnant in 3months, or who are not doing\n             contraceptive\n\n          -  Subjects who participated in other studies within 30 days or were not passed over 5\n             times of half life for investigational product\n\n          -  Subjects who are having trouble with acute disease\n\n          -  Subjects who have taken any treatment that can affect to glabellar lines and/or any\n             lines around forehead within the previous 6 months\n\n          -  Subjects who are unable to communicate or follow the instructions\n\n          -  Subjects who are not eligible for this study based on investigator's judgement"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "262", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01791920", 
            "org_study_id": "HG-11-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Botulinum toxin type A(Botox\u00ae)", 
                "description": "Single administration, Day 0, 20 units", 
                "intervention_name": "Botulinum toxin type A(Botulax\u00ae)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Botulinum toxin type A (Botulax\u00ae)", 
                "description": "Single administration, Day 0, 20units", 
                "intervention_name": "Botulinum toxin type A(Botox\u00ae)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 13, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Dongjak-gu"
                    }, 
                    "name": "Chung-Ang University Hopspital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Jongno-Gu"
                    }, 
                    "name": "Seoul National University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Jung-Gu"
                    }, 
                    "name": "National Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Nowon-Gu"
                    }, 
                    "name": "Eulji General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Seocho-Gu"
                    }, 
                    "name": "The catholic university of Korea, Seoul ST. Mary's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Seongbuk-Gu"
                    }, 
                    "name": "Korea University Anam Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double-blinded, Randomized, Active Control Comparative, Multicenter-designed, Phase III Clinical Trial to Evaluate the Safety and Efficacy for Improvement of Glabellar Lines of \"Botulax\u00ae\" Compared to Botox Inj. in Patients With Moderate to Severe Glabellar Lines", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Improvement rate of glabellar lines at maximum frown with Physician's rating of lines severity at 4weeks post injection.", 
            "measure": "Responder rate of  improvement in glabellar lines with Physician's rating of line severity", 
            "safety_issue": "No", 
            "time_frame": "at 4 weeks post-injection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01791920"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety evaluation in experimental drug treatment group", 
                "safety_issue": "Yes", 
                "time_frame": "4, 8, 12, 16 weeks post-injection"
            }, 
            {
                "description": "Improvement rate of glabellar lines at maximum frown with Physician's rating of lines severity at 8, 12, 16weeks post injection.", 
                "measure": "Responder rate of improvement in glabellar lines with Physician's rating of line severity", 
                "safety_issue": "No", 
                "time_frame": "8, 12, 16 weeks post-injection"
            }, 
            {
                "description": "Improvement rate of glabellar lines at rest with investigator's live assessment of severity at 4, 8, 12, 16weeks post injection", 
                "measure": "Responder rate of improvement in glabellar lines at rest with investigator's live assessment of severity", 
                "safety_issue": "No", 
                "time_frame": "4, 8, 12, 16 weeks post-injection"
            }, 
            {
                "description": "Improvement rate of glabellar lines at maximum frown with investigator's photo assessment at 4, 8, 12, 16weeks post injection", 
                "measure": "Responder rate of improvement in glabellar lines at maximum frown with investigator's photo assessment", 
                "safety_issue": "No", 
                "time_frame": "4, 8, 12, 16 weeks post-injection"
            }, 
            {
                "description": "Improvement rate of glabellar lines at rest with investigator's photo assessment at 4, 8, 12, 16weeks post injection", 
                "measure": "Responder rate of improvement in glabellar lines at rest with investigator's photo assessment", 
                "safety_issue": "No", 
                "time_frame": "4, 8, 12, 16 weeks post inejection"
            }, 
            {
                "description": "Improvement rate of glabellar lines with Subject's improvement assessment at 4, 8, 12, 16weeks post injection", 
                "measure": "Responder rate of improvement in glabellar lines with Subject's improvement assessment", 
                "safety_issue": "No", 
                "time_frame": "4, 8, 12, 16 weeks post-injections"
            }, 
            {
                "description": "Subject's satisfaction rate of improvement in glabellar lines at 4, 8, 12, 16 weeks post injection", 
                "measure": "Subject's satisfaction rate", 
                "safety_issue": "No", 
                "time_frame": "4, 8, 12, 16 weeks post-injection"
            }
        ], 
        "source": "Hugel", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hugel", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}